Evidence map›Paper›PMID 41104077›Full record

ArticleFrontiers in health services2025

Rectal treatment in ulcerative colitis; a qualitative study exploring reasons for under utilisation.

Jean-Pierre Rothen, Florence Moerlen, Céline von Büren, Samuel Allemann, Isabelle Arnet

Abstract read
In one paragraph

Article in Frontiers in health services, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jean-Pierre RothenPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Florence MoerlenPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Céline von BürenPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Samuel AllemannPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Isabelle ArnetPharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ulcerative colitis is an inflammatory bowel disease that is limited to the colon. First-line treatment consists of rectally administered suppositories, foam or enema. Adherence to rectal treatment is very low in people with ulcerative colitis. We aimed to explore modifiable factors influencing adherence to rectal treatment among patients, healthcare providers (HCP), and pharmaceutical companies, and to delineate new approaches to improve adherence to rectal medicines. Methods: We recruited people using rectal treatment, community and clinical pharmacists, gastroenterologists, inflammatory bowel diseases (IBD) nurses, and representatives of pharmaceutical companies specialised in the production of rectal therapies. We performed semi-structured one-to-one interviews tackling the three pivotal topics knowledge and beliefs, product characteristics, and communication. We started with patient interviews whose statements served to inform the other interviews. All interviews were the subject of a keyword protocol, audio-recorded, and transcribed. Thematic analysis was used with inductive approach for the patients, and deductive approach for all other interviewees. Identified themes were compared and agreements and divergences were compiled. Results: We interviewed eight patients (22-77 years old, 3 women) in spring 2023, and stakeholders from the hospital (3 gastroenterologists and 2 IBD nurses), ambulatory setting (4 community pharmacists) and pharmaceutical companies (2 representatives) in 2024, all in the region of Basel (Switzerland). Overall, people with ulcerative colitis often feel left alone to cope with the challenges associated with their therapies. Pretreatment concerns and difficulties experienced by these people following their first attempts at use are not adequately addressed by HCPs. Training sessions for clinicians and pharmacists, patient-oriented demonstration materials, visual aids, and tips and tricks the application of rectal treatment could help improve the use of rectal medicines by people with ulcerative colitis. Conclusion: This study identified a detailed knowledge of the proper use of rectal treatment and frank communication between patients and HCPs as crucial for the adherence to rectally administered medicines. While these factors are broadly recognised in the literature, this study highlights their common priority among all stakeholders. In addition, solutions for future development and tailored interventions are proposed.

Indexed as

adherencereal-world datarectal treatmentstakeholderulcerative colitis

Identifiers

PMID41104077
PMCPMC12521153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.